These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9814057)

  • 61. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 64. The role of chemotherapy in prostate cancer. Minireview.
    Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
    Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Overcoming drug resistance in patients with metastatic breast cancer.
    Wong ST; Goodin S
    Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Is overcoming hormone resistance in breast cancer possible?
    Orphanos G; Kakoullou N; Ardavanis A
    J BUON; 2008; 13(3):315-22. PubMed ID: 18979544
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular pharmacodynamics in childhood leukemia.
    Pieters R; den Boer ML
    Int J Hematol; 2003 Dec; 78(5):402-13. PubMed ID: 14704032
    [No Abstract]   [Full Text] [Related]  

  • 70. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.
    Sawicka M; Kalinowska M; Skierski J; Lewandowski W
    J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chemotherapy for retinoblastoma.
    Chan HS; Gallie BL; Munier FL; Beck Popovic M
    Ophthalmol Clin North Am; 2005 Mar; 18(1):55-63, viii. PubMed ID: 15763191
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Treatment of cancer: surgery, radiotherapy, chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and informing the patient].
    Besse B; Soria JC
    Rev Prat; 2007 Feb; 57(4):429-40; quiz 440. PubMed ID: 17455746
    [No Abstract]   [Full Text] [Related]  

  • 73. The history of DNA reactive antitumour agents: is newer better?
    Gibson NW
    J Pharm Pharmacol; 1993 Apr; 45 Suppl 1():331-42. PubMed ID: 8098740
    [No Abstract]   [Full Text] [Related]  

  • 74. [Antineoplastic chemotherapy (hormone therapy included): classification, main secondary effects].
    Brun B; Piedbois P
    Rev Prat; 1998 Sep; 48(14):1587-600. PubMed ID: 9814057
    [No Abstract]   [Full Text] [Related]  

  • 75. [Development of cancer chemotherapy. The discovery of new active drugs. II].
    Lopez M
    Clin Ter; 1998; 149(6):453-9. PubMed ID: 10100409
    [No Abstract]   [Full Text] [Related]  

  • 76. Management of hormone-refractory disease.
    Hennequin C
    BJU Int; 2004 Dec; 94 Suppl 3():16-7. PubMed ID: 15521889
    [No Abstract]   [Full Text] [Related]  

  • 77. Advances in chemotherapy options for metastatic breast cancer: introduction of epothilones.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):29-30. PubMed ID: 17824553
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.